Eurofins Scient (OTCMKTS:ERFSF) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Eurofins Scient (OTCMKTS:ERFSF) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company.

Several brokerages recently weighed in on ERFSF. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Eurofins Scient in a research report on Wednesday, October 29th. Citigroup reissued a “neutral” rating on shares of Eurofins Scient in a report on Wednesday, October 22nd. Finally, BNP Paribas Exane raised Eurofins Scient to an “outperform” rating in a report on Monday, January 5th.

Eurofins Scient Stock Down 3.2%

OTCMKTS:ERFSF opened at $83.00 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.19 and a current ratio of 1.26. Eurofins Scient has a fifty-two week low of $48.55 and a fifty-two week high of $86.20. The firm has a 50-day simple moving average of $74.97 and a two-hundred day simple moving average of $74.34.

About Eurofins Scient

Eurofins Scientific is a global provider of bioanalytical testing and laboratory services, offering a wide array of testing solutions to pharmaceutical, food, environmental, agriscience and consumer products industries. Its core services include pharmaceutical quality control, environmental testing for water and air quality, food safety analysis, agrochemical trials and clinical diagnostic support. The company operates specialized laboratories equipped with advanced analytical technologies such as chromatography, mass spectrometry and molecular biology to ensure compliance with regulatory standards and to support research and development efforts across multiple sectors.

Founded in 1987 by Gilles Martin and headquartered in Luxembourg, Eurofins has grown through a combination of organic expansion and strategic acquisitions.